MacuCLEAR and Mystic Pharmaceuticals have announced preliminary results of phase Ib clinical trial for the treatment and prevention of the progression of Age Related Macular Degeneration (AMD).
According to the company, the preliminary results indicated that MacuCLEAR’s MC-1101 drug is safe and well tolerated by study participants, and has a biological effect on blood flow in the back of the retina.
The company said that the Mystic’s VersiDoser ophthalmic delivery system was used by trial participants to self-administer MC-1101 to the front of the eye during the trial. The study included Proof Of Concept (POC) indicators. A key finding of the study was the successful migration of the drug to the back of the eye.
The company said that by using special laser Doppler flow instrumentation, it showed MC-1101 gets to the back of the eye and modulates the blood flow in the choroid, the tiny blood vessels in the back of the macula portion of the retina
Philip Ralston, Jr, president and CEO of MacuCLEAR, said: “We are very pleased with the groundbreaking results of this study. We have confirmed the safety of MC-1101 in humans, a primary endpoint for the study. We are excited about the implications of the proof of concept part of this study.
“This study provides additional scientific evidence supporting our theory that restoring blood flow in the choroid will have a positive affect on preventing the progression of this terrible disease that is the leading cause of blindness for people over the age of 50 in the world.”